IL308045A - טיפול במחלת לופוס נפריטיס באמצעות נוגדנים אנטי-באפריים - Google Patents
טיפול במחלת לופוס נפריטיס באמצעות נוגדנים אנטי-באפרייםInfo
- Publication number
- IL308045A IL308045A IL308045A IL30804523A IL308045A IL 308045 A IL308045 A IL 308045A IL 308045 A IL308045 A IL 308045A IL 30804523 A IL30804523 A IL 30804523A IL 308045 A IL308045 A IL 308045A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- lupus nephritis
- baffr antibodies
- baffr
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184046P | 2021-05-04 | 2021-05-04 | |
| PCT/IB2022/054056 WO2022234440A1 (en) | 2021-05-04 | 2022-05-03 | Treatment for lupus nephritis using anti-baffr antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308045A true IL308045A (he) | 2023-12-01 |
Family
ID=81655080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308045A IL308045A (he) | 2021-05-04 | 2022-05-03 | טיפול במחלת לופוס נפריטיס באמצעות נוגדנים אנטי-באפריים |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240239911A1 (he) |
| EP (1) | EP4334352A1 (he) |
| JP (1) | JP2024517796A (he) |
| KR (1) | KR20240004760A (he) |
| CN (1) | CN117203240A (he) |
| CA (1) | CA3216063A1 (he) |
| IL (1) | IL308045A (he) |
| TW (1) | TW202302147A (he) |
| WO (1) | WO2022234440A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121752276A (zh) * | 2023-09-08 | 2026-03-27 | 菲特治疗公司 | 用于自身免疫疾病治疗的iPSC衍生的效应细胞 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101120021A (zh) * | 2004-12-31 | 2008-02-06 | 基因技术公司 | 结合br3的多肽及其用途 |
| SI2315780T1 (sl) * | 2008-07-17 | 2015-11-30 | Novartis Ag | Sestavki in postopki uporabe za terapevtska protitelesa |
| WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
-
2022
- 2022-05-03 TW TW111116733A patent/TW202302147A/zh unknown
- 2022-05-03 KR KR1020237041227A patent/KR20240004760A/ko active Pending
- 2022-05-03 WO PCT/IB2022/054056 patent/WO2022234440A1/en not_active Ceased
- 2022-05-03 EP EP22723784.9A patent/EP4334352A1/en active Pending
- 2022-05-03 IL IL308045A patent/IL308045A/he unknown
- 2022-05-03 JP JP2023567138A patent/JP2024517796A/ja active Pending
- 2022-05-03 CA CA3216063A patent/CA3216063A1/en active Pending
- 2022-05-03 CN CN202280030909.4A patent/CN117203240A/zh active Pending
- 2022-05-03 US US18/558,730 patent/US20240239911A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024517796A (ja) | 2024-04-23 |
| KR20240004760A (ko) | 2024-01-11 |
| EP4334352A1 (en) | 2024-03-13 |
| CN117203240A (zh) | 2023-12-08 |
| TW202302147A (zh) | 2023-01-16 |
| US20240239911A1 (en) | 2024-07-18 |
| WO2022234440A1 (en) | 2022-11-10 |
| CA3216063A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279063A (he) | תאי t לקולטן אנטיגן כימרי לטיפול בסרטן | |
| IL281449A (he) | נוגדנים אנטי- ifnar1 לטיפול במחלות אוטואימוניות | |
| IL277861A (he) | נוגדנים ספציפיים ל axl לטיפול בסרטן | |
| PL3728271T3 (pl) | Związki makrocykliczne do leczenia chorób | |
| EP3990022A4 (en) | Anti-cd33 antibodies for treating cancer | |
| ZA201907460B (en) | Improved protocol for treatment of lupus nephritis | |
| GB201911685D0 (en) | Process for purifying monoclonal antibodies | |
| IL289842A (he) | נוגדנים אנטי- liv1 אנושיים לטיפול בסרטן | |
| IL276875A (he) | נוגדנים אנטי cd6 לטיפול באסתמה חמורה | |
| IL289201A (he) | תרכובות לטיפול בסרטן | |
| GB201909468D0 (en) | Compounds for treating cancer | |
| SG11202007924TA (en) | Method for introducing mutations | |
| IL277056A (he) | שיטה לטיהור נוגדנים | |
| IL308045A (he) | טיפול במחלת לופוס נפריטיס באמצעות נוגדנים אנטי-באפריים | |
| IL308393A (he) | נוגדנים לטיפול במחלות אלפא-סינוקליאיניות | |
| IL289959A (he) | שיטות לטיהור נוגדנים | |
| IL284668A (he) | שיטות לטיפול בסכיזופרניה | |
| IL290582A (he) | שיטה לסינתזה של פניל-5-הידרוקסי מתיל-2- אוקסאזולידינון מותמרים ב-n | |
| IL308044A (he) | טיפול בלופוס אריתמטוזוס מערכתי באמצעות נוגדנים אנטי-באפריים | |
| SG11202102683XA (en) | Treatment for obesity | |
| GB201909466D0 (en) | Compounds for treating cancer | |
| HK40039204A (en) | Anti-ifnar1 antibodies for treating autoimmune diseases | |
| HK40109315A (en) | Antibodies for treating alpha-synucleinopathies | |
| HK40046198A (en) | Axl-specific antibodies for cancer treatment | |
| GB201903547D0 (en) | Treatment for autoimmune diseases |